Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/153952 International Application No.: PCT/IB2017/051399
Publication Date: 14.09.2017 International Filing Date: 09.03.2017
C07C 311/21 (2006.01) ,C07C 311/29 (2006.01) ,C07C 311/44 (2006.01) ,A61K 31/145 (2006.01) ,A61P 31/18 (2006.01) ,A61P 35/00 (2006.01) ,C07D 215/38 (2006.01) ,C07D 317/66 (2006.01) ,C07D 231/42 (2006.01) ,C07D 333/36 (2006.01) ,C07D 333/66 (2006.01) ,C07D 235/04 (2006.01) ,C07D 471/04 (2006.01) ,C07D 251/72 (2006.01) ,C07D 261/02 (2006.01) ,C07D 263/50 (2006.01) ,C07D 209/40 (2006.01) ,C07D 307/82 (2006.01) ,A61K 31/47 (2006.01) ,A61K 31/498 (2006.01) ,A61K 31/335 (2006.01) ,A61K 31/381 (2006.01) ,A61K 31/404 (2006.01) ,A61K 31/416 (2006.01) ,A61K 31/4184 (2006.01) ,A61K 31/428 (2006.01)
[IPC code unknown for C07C 311/21][IPC code unknown for C07C 311/29][IPC code unknown for C07C 311/44][IPC code unknown for A61K 31/145][IPC code unknown for A61P 31/18][IPC code unknown for A61P 35][IPC code unknown for C07D 215/38][IPC code unknown for C07D 317/66][IPC code unknown for C07D 231/42][IPC code unknown for C07D 333/36][IPC code unknown for C07D 333/66][IPC code unknown for C07D 235/04][IPC code unknown for C07D 471/04][IPC code unknown for C07D 251/72][IPC code unknown for C07D 261/02][IPC code unknown for C07D 263/50][IPC code unknown for C07D 209/40][IPC code unknown for C07D 307/82][IPC code unknown for A61K 31/47][IPC code unknown for A61K 31/498][IPC code unknown for A61K 31/335][IPC code unknown for A61K 31/381][IPC code unknown for A61K 31/404][IPC code unknown for A61K 31/416][IPC code unknown for A61K 31/4184][IPC code unknown for A61K 31/428]
ADAMS, Jerry Leroy; US
DUFFY, Kevin J.; US
MOORE, Michael Lee; US
NEIPP, Christopher E.; US
RALPH, Jeffrey M.; US
SQUIRE, Michael Damien; US
Priority Data:
(EN) The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
(FR) L'invention concerne des dérivés salicylamide substitués. Spécifiquement, l'invention concerne des composés représentés par la formule I : (I) dans laquelle R, R1 et R2 sont tels que définis dans la description, ou un sel de ceux-ci pharmaceutiquement acceptable. Les composés de l'invention sont des inhibiteurs de CD73 et peuvent être utiles dans le traitement du cancer, de syndromes précancéreux et de maladies associées à l'inhibition de CD73, telles que le SIDA, le traitement du VIH, les maladies auto-immunes, les infections, l'athérosclérose, et une lésion de reperfusion ischémique. Par conséquent, l'invention concerne en outre des compositions pharmaceutiques comprenant un composé de l'invention. L'invention concerne enfin des procédés d'inhibition de l'activité de CD73 et le traitement de troubles associés à celui-ci à l'aide d'un composé de l'invention ou d'une composition pharmaceutique comprenant un composé de l'invention.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)